Paul K. Paik, MD

Paul K. Paik, MD, a medical oncologist and clinical director of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center, discusses the newest data from the VISION trial (NCT02864992) of tepotinib (Tepmetko) in patients with non–small cell lung cancer and a 

After the newer data cutoff of July 2020 for cohort A of the VISION study, the investigators were able to evaluate updated, more longitudinal findings. Paik says that the data from this cohort held up in terms of consistency for the overall response rate (ORR), as well as the median progression-free survival (PFS). The ORR was 46% and the median PFS was 9 months with the study drug.

The investigators explored the demographic information in VISION and how the patient demographics relate to response to tepotinib, especially in terms of how many therapies patients had previously received. When compared with patients who were treatment naïve, those who had received prior therapy had similar results and the data were consistent for efficacy in the 2 groups. Patients who were previously treated immunotherapy, chemotherapy, or chemoimmunotherapy all had consistent efficacy data as well, with an ORR in the 40% range. The take home message of this newer data is that the efficacy stays consistent with further time and different demographics, according to Paik.

Videos

Paul K. Paik, MD, discusses the newest data from the VISION trial of tepotinib in patients with non–small cell lung cancer and a MET exon 14 skipping mutations.

Update of VISION Trial Shows Continued Efficacy of Tepotinib in NSCLC

Paul K. Paik, MD, a medical oncologist and clinical director of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center, discusses the benefits to using liquid biopsy compared to a tissue biopsy, particularly in the phase II VISION trial in which patients with nonsmall cell lung cancer (NSCLC) harboring MET alterations were treated with tepotinib. Patients were divided into 2 cohorts based on whether they were enrolled with either a liquid biopsy or tumor biopsy.

A unique feature of this trial is that patients could get a liquid biopsy to enroll; tissue biopsy was not a necessary component for enrollment to be included in the VISION trial. Paik says that the data collected and analyzed in the liquid biopsy cohort were similar to that of the tissue biopsy cohort. Rates of response were similar whether patients received a liquid biopsy or tumor biopsy, by both independent and investigator assessments.

Paul K. Paik, MD, discusses the benefits to using liquid biopsy compared to a tissue biopsy, particularly in the phase II VISION trial in which patients with non&ndash;small cell lung cancer harboring MET alterations were treated with tepotinib. Patients were divided into 2 cohorts based on whether they were enrolled with either a liquid biopsy or tumor biopsy.

VISION Trial Demonstrates Liquid Biopsy Is Comparable to Tissue Biopsy for NSCLC

Paul K. Paik, MD, clinical director, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, discusses recent chemotherapy and immunotherapy advances in the treatment of squamous cell lung cancer.

Paul K. Paik, MD | Authors

Articles

Update of VISION Trial Shows Continued Efficacy of Tepotinib in NSCLC

VISION Trial Demonstrates Liquid Biopsy Is Comparable to Tissue Biopsy for NSCLC

Advances in the Treatment of Squamous Cell Lung Cancer